Company intelligence / Profile preview

Katama Pharmaceuticals

Montreal, Canada

Ownership: Private
Development stage: Other

Overview

Katama Pharmaceuticals was a Montreal-based biotech company focused on developing targeted oncology drugs and small molecule therapeutics. It was acquired by Theratechnologies on February 25, 2019, for $8.1 million. At the time of acquisition, its pipeline included a clinical-stage small molecule program (tolperisone) for acute painful muscle spasms.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sanochemia

Beyond the preview

Go deeper on Katama Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Katama Pharmaceuticals.

Explore the full profile